TY  - GEN
AU  - Leblond,Véronique
AU  - Morel,Pierre
AU  - Dilhuidy,Marie-Sarah
AU  - Leleu,Xavier
AU  - Soussain,Carole
AU  - Leprête,Stéphane
AU  - Dreyfus,Brigitte
AU  - Dartigeas,Caroline
AU  - Mahé,Béatrice
AU  - Anglaret,Bruno
AU  - Pégourié,Brigitte
AU  - Besson,Caroline
AU  - Aurran,Thérèse
AU  - Vekhoff,Anne
AU  - Tournilhac,Olivier
AU  - Banos,Anne
AU  - Oya,Hervé
AU  - Lejeune,Julie
AU  - Ouzegdouh,Maya
AU  - Chevret,Sylvie
TI  - A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone
SN  - 1029-2403
PY  - 2018///0417
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Bayes Theorem
KW  - Bortezomib
KW  - administration & dosage
KW  - Dexamethasone
KW  - Female
KW  - Hematologic Diseases
KW  - chemically induced
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Middle Aged
KW  - Prospective Studies
KW  - Remission Induction
KW  - Waldenstrom Macroglobulinemia
KW  - drug therapy
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1080/10428194.2017.1307357
ER  -